[Skip to Content]
[Skip to Content Landing]
Views 1,083
Citations 0
Research Letter
November 5, 2018

Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes

Author Affiliations
  • 1Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora
  • 2School of Public Health, University of Colorado Anschutz Medical Campus, Aurora
  • 3Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota
JAMA Intern Med. Published online November 5, 2018. doi:10.1001/jamainternmed.2018.5142

Cannabis use is increasing with the shifts in legality and public perceptions in the United States.1 Studies have reported improvement in insulin sensitivity and pancreatic beta cell function with cannabis use,2,3 generating widespread media attention suggesting cannabis as a potential therapeutic agent for treatment of type 2 diabetes. By contrast, we published a case series4 reporting recurrent diabetic ketoacidosis (DKA) with cannabis use in patients with type 1 diabetes (T1D). Because little is known about cannabis use and its contribution to DKA in T1D, we investigated the characteristics of cannabis use among adults with T1D and the association of cannabis use with DKA.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×